Form 4: Boston Scientific EVP Wendy Carruthers Executes Stock Options and Sells Shares Under 10b5-1 Plan

Wendy Carruthers, EVP of Human Resources at Boston Scientific, exercised stock options and sold shares of common stock on May 1, 2024, under a pre-established Rule 10b5-1 trading plan.

Summary

• On May 1, 2024, Wendy Carruthers, the EVP of Human Resources at Boston Scientific, executed stock options to acquire 3,066 shares at $17.26 and 1,197 shares at $24.55.
• Carruthers also sold 6,983 shares of Boston Scientific common stock at $71.47.
• These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.
• Following these transactions, Carruthers directly owns 48,348 shares of Boston Scientific common stock and holds options to purchase 43,024 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative implications for the company.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, which can provide some reassurance that the sales were planned and not based on insider information.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without being accused of acting on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The vesting schedules of these options, such as the four equal annual installments mentioned, are typical in the industry.
• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies, including competitors like Medtronic (MDT) and Abbott Laboratories (ABT), to manage their stock sales in compliance with insider trading regulations.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates